1 of 1
Story summary
- UCB, a biopharmaceutical company based in Brussels, Belgium, will acquire Neurona Therapeutics, a biotechnology company, for up to $1.15 billion.
- The deal includes an upfront payment of $650 million and $500 million in potential milestones.
- Neurona Therapeutics' candidate NRTX-1001 is a regenerative cell therapy for drug-resistant mesial temporal lobe epilepsy (mTLE) in phase I/II trials.
- The transaction is expected to close by the end of Q2 2026, pending regulatory approvals.
